Compare KNOP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNOP | IPHA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United Kingdom | France |
| Employees | 874 | 163 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.1M | 189.5M |
| IPO Year | 2012 | N/A |
| Metric | KNOP | IPHA |
|---|---|---|
| Price | $11.45 | $2.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 82.3K | ★ 126.4K |
| Earning Date | 05-19-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.51 | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.16 | $1.18 |
| 52 Week High | $11.55 | $2.63 |
| Indicator | KNOP | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 65.66 |
| Support Level | $10.04 | $1.72 |
| Resistance Level | $11.55 | $2.34 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 89.01 | 68.85 |
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.